In recent years there has been increasing interest in the study of circulating tumor cells (CTC) and plama cell-free circulating DNA (cfDNA) as a new biomarker in neoplastic diseases. Our work aims to clarify its clinical role in ovarian epithelial carcinoma (OEC).
A prospective, multicenter, observational study has been conducted for 3 years in patients with advanced or responsive OEC. The predictive value and prognosis of CTC and cfDNA have been determined for both progression-free survival (PFS) and overall survival (OS). Their values have been compared with a control group. CTC were analysed by the CellSearch method and cfDNA by ALU-sequences-based quantitative PCR using two primers (ALU115 and ALU247); cfDNA integrity was calculated by ALU247/ALU115 ratio. This study was approved by the Central Research Ethics Committee. Updated data are presented.
This study was conducted from November 2013 until December 2016. We recruited 88 patients, 15 benign tumors and 16 healthy subjects. Clinical characteristics were similar to other series, with a mean age of 57 years, 68.2% serous high grade subtype and 55.7% with stage IIIC. CTC were positive in 23.8% of patients (>1CTC/7,5mL). Levels of cfDNA were significantly elevated in patients than in the group of benign tumors and healthy control. CTC proved to be a negative prognostic factor of OS, with an average of 19.8 months versus 30.4 months (log-rank 4,649, p
In summary, CTC and cfDNA in advanced ovarian epithelial carcinoma have been prognostic factors for survival. In addition, cfDNA has a predictive value of response. These two biomarkers may be useful in clinical practice.
Clinical trial identification
Legal entity responsible for the study
University Clinical Hospital Virgen Arrixaca - Murcia/ES
All authors have declared no conflicts of interest.